Personalized medicine has the potential to dramatically improve the way we develop new drugs; eliminating the health risk, inefficiency and financial cost arising from the practice of developing and prescribing drugs for patients who are unlikely to be responders. Among the many strategic challenges facing the global biopharma industry, perhaps the highest priority is to increase the likelihood of approval of drugs in the pipeline by identifying the profile of drug responders much earlier in the development cycle.
Synexa has performed extensive genotyping analysis for the identification of metabolism profiles and responders vs. non-responders, to help improve therapeutic product development and stratify patient populations for clinical trials. In addition, Synexa offers large scale gene expression analyses enabling the identification of individual biomarkers with distinct dysregulation between states and sets of genes acting in concert to affect cellular processes. We can also analyse a host of genetic biomarkers using the latest technology on a wide variety of sample matrices including challenging samples such as FFPE.
Pharmacogenetic testing plays a pivotal role in pre-clinical and early phase clinical stages by assessing the two most important concerns when developing a new drug: efficacy and safety. Information on these two parameters at an early stage can greatly reduce the risk of late stage drug failure. Synexa offers extensive genotyping analyses to help guide therapeutic product development, treatment choices and optimal dose selection. In addition to relatively routine genetic screening assays/mutation detection for various genes involved in drug metabolism and cancer, we offer specialty genomic services such as customized assay development, validation and testing. Our assays include identifying common and rare mutations, single nucleotide polymorphism, copy number variants and other genetic changes that can contribute to complex diseases or drug response.
Our genotyping services include:
Pharmacogenetic testing generates large amounts of data that require sophisticated analyses. We offer in-depth data analysis and interpretation to match study outputs and goals. Our key focus is providing clients with genotyping data and to determine the effect this may have on the metabolism of candidate drugs. Extensive genotyping analysis enables clients to distinguish responder from non-responder phenotypes, aiding in the appropriate selection of patients for a trial and increasing candidate drug success rates. Importantly, such analyses also help guide optimal drug dosage reducing the incidence of serious adverse events due to drug toxicity.
Gene expression profiling allows us to identify individual biomarkers with distinct dysregulation between two states and sets of genes acting in concert to affect cellular processes. Synexa can analyse a host of genetic biomarkers including mRNA and miRNA using the latest and most sophisticated technology on a wide variety of sample matrices.
Our pharmacogenetics laboratory offers:
The challenge no longer lies in simply obtaining gene expression profiles, but rather in the interpretation of the complex patterns and associations in the data to generate insights to underlying biological mechanisms and response to disease and drug. Synexa offers in-depth data analysis and interpretation ensuring that changes in biological processes that are distributed across an entire network of genes are not missed. We focus on turning big data generated by various genomic platforms into insight, using sophisticated bioinformatic approaches.